One week before the trial and in the last week of treatment participants were assessed in respect to ( i ) motor and general symptoms score ( UPDRS ) ; ( ii ) well-being and quality of life ( PDQ-@ ) ; and ( iii ) possible neuroprotective effects ( BDNF and H ( @ ) - MRS ) .